Ionis Pharmaceuticals Inc

IONS: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
#%LOCK|cdTV!LOCK|&Z^Fbq^

Ionis Earnings: Tryngolza Commercial Launch Underway; Shares Very Undervalued

Narrow-moat Ionis Pharmaceuticals reported solid 2024 results highlighted by total revenue of $705 million and a portfolio that continues to make progress. Ionis is tracking our expectations, and we maintain our $69 fair value estimate. We view the shares as very undervalued, trading at an attractive entry point for long-term investors with a high degree of risk tolerance.

Sponsor Center